BASEL, Switzerland and BOSTON, MA, May 1, 2026
Noema Pharma AG announced the presentation of positive Phase 2a clinical data for its investigational therapy cendifensine in menopausal women suffering from moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting. The results highlight a strong efficacy signal and favorable tolerability profile, positioning cendifensine as a promising non-hormonal treatment option in an area with significant unmet medical need.
Strong Symptom Reduction and Multi-Dimensional Benefits
The Phase 2a study demonstrated clinically meaningful reductions in both frequency (92%) and severity (59%) of vasomotor symptoms over 12 weeks, indicating a robust therapeutic effect in a patient population that often has limited alternatives to hormone therapy. In addition to reducing hot flashes, patients treated with cendifensine experienced improvements in depressive symptoms, fatigue, and food cravings, suggesting a broader impact on overall menopausal health.
Notably, participants also showed a median weight loss of 2.5 kg, which is particularly relevant given the metabolic changes commonly associated with menopause. These results reinforce the potential of cendifensine to address multiple interconnected symptoms through a single mechanism, differentiating it from existing treatments that typically focus on symptom-specific relief.
First-in-Class Mechanism Targets Neurotransmitter Balance
Advertisement
Cendifensine is a first-in-class, oral broad-spectrum monoamine modulator designed to rebalance key neurotransmitters including serotonin, norepinephrine, and dopamine, which are believed to play a central role in thermoregulation and mood control. Unlike hormone replacement therapies, which carry safety concerns and are not suitable for all patients, cendifensine offers a non-hormonal therapeutic approach that directly targets underlying neurological pathways.
This mechanism may explain the observed multi-symptom benefits, including mood stabilization and reduced fatigue, making it a potentially holistic treatment option for menopausal women. The drug’s ability to simultaneously influence multiple neurotransmitter systems positions it uniquely in the evolving landscape of menopause care.
Advancement Toward Phase 2b Clinical Development
Based on the strength of the Phase 2a results, Noema Pharma plans to advance cendifensine into a randomized, placebo-controlled Phase 2b trial to further evaluate its efficacy and safety in a larger patient population. The upcoming study will be critical in confirming the drug’s therapeutic potential and defining its clinical profile for future regulatory pathways.
The data were presented in a scientific poster session at ACOG 2026, reflecting growing interest in innovative, non-hormonal solutions for menopause-related conditions. With millions of women affected globally and limited approved treatment options in key markets, cendifensine could represent a significant advancement in women’s health therapeutics if future trials confirm these findings.
Noema Pharma continues to build a diversified pipeline of oral small molecule therapies targeting neurological and systemic conditions, with a focus on areas where current treatment options are inadequate. The promising data from this study underscore the company’s strategy of developing mechanism-driven therapies that address complex, multi-symptom disorders through targeted modulation of biological pathways.
Source: Noema Pharma press release
